Street Calls of the Week
Investing.com -- Armata Pharmaceuticals (NYSE American:ARMP) stock surged 95% following the announcement of positive Phase 2a clinical trial results for its bacteriophage treatment targeting complicated Staphylococcus aureus bacteremia.
The biotechnology company presented data from its diSArm study at IDWeek 2025, showing that its AP-SA02 therapy, when combined with best available antibiotic therapy, achieved significantly higher clinical response rates compared to placebo. At day 12, patients receiving AP-SA02 demonstrated an 88% clinical response rate versus 58% in the placebo group, as assessed by blinded site investigators.
Notably, no patients in the AP-SA02 treatment group experienced non-response or relapse at follow-up assessments, while approximately 25% of placebo patients did. The therapy showed efficacy against both methicillin-resistant and methicillin-sensitive S. aureus infections, which were present in similar proportions across treatment groups.
"The results of the diSArm study confirm, for the first time in a randomized clinical trial, the efficacy of intravenous phage therapy for S. aureus bacteremia," stated Dr. Loren G. Miller, who presented the findings at IDWeek.
The treatment was well-tolerated with no serious adverse events related to the study drug. Only two treatment-emergent adverse events occurred in the AP-SA02 group, including one case of transient liver enzyme elevation and one hypersensitivity reaction that resolved after discontinuation of vancomycin.
Armata plans to advance AP-SA02 into a pivotal Phase 3 trial in 2026, pending FDA review and feedback. The company is currently engaged with regulators regarding a potential superiority trial design.
The positive results represent a significant milestone in the development of bacteriophage therapeutics as a potential new approach for treating antibiotic-resistant bacterial infections.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.